DrugPatentWatch Database Preview
NYMALIZE Drug Profile
» See Plans and Pricing
When do Nymalize patents expire, and when can generic versions of Nymalize launch?
Nymalize is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are four patents protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in NYMALIZE is nimodipine. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the nimodipine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nymalize
A generic version of NYMALIZE was approved as nimodipine by HERITAGE PHARMS INC on May 2nd, 2007.
Summary for NYMALIZE
| International Patents: | 2 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 106 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,908 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NYMALIZE |
| What excipients (inactive ingredients) are in NYMALIZE? | NYMALIZE excipients list |
| DailyMed Link: | NYMALIZE at DailyMed |
Recent Clinical Trials for NYMALIZE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Johns Hopkins University | Early Phase 1 |
Pharmacology for NYMALIZE
| Drug Class | Dihydropyridine Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists |
US Patents and Regulatory Information for NYMALIZE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbor Pharms Llc | NYMALIZE | nimodipine | SOLUTION;ORAL | 203340-001 | May 10, 2013 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Arbor Pharms Llc | NYMALIZE | nimodipine | SOLUTION;ORAL | 203340-002 | Apr 8, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Arbor Pharms Llc | NYMALIZE | nimodipine | SOLUTION;ORAL | 203340-002 | Apr 8, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NYMALIZE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 03093108 | Start Trial |
| Australia | 2003221794 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
